Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNN 
Smith & Nephew SNATS Inc (SNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: SNN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $37.43
1 Year Target Price $37.43
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.81% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.42B USD | Price to earnings Ratio 31.44 | 1Y Target Price 37.43 |
Price to earnings Ratio 31.44 | 1Y Target Price 37.43 | ||
Volume (30-day avg) 4 | Beta 0.67 | 52 Weeks Range 23.11 - 38.47 | Updated Date 10/14/2025 |
52 Weeks Range 23.11 - 38.47 | Updated Date 10/14/2025 | ||
Dividends yield (FY) 2.16% | Basic EPS (TTM) 1.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) 14.49% |
Management Effectiveness
Return on Assets (TTM) 5.81% | Return on Equity (TTM) 9.14% |
Valuation
Trailing PE 31.44 | Forward PE 13.61 | Enterprise Value 18188355732 | Price to Sales(TTM) 2.59 |
Enterprise Value 18188355732 | Price to Sales(TTM) 2.59 | ||
Enterprise Value to Revenue 3.07 | Enterprise Value to EBITDA 13.71 | Shares Outstanding 423839772 | Shares Floating 865574477 |
Shares Outstanding 423839772 | Shares Floating 865574477 | ||
Percent Insiders 0.03 | Percent Institutions 7.95 |
Upturn AI SWOT
Smith & Nephew SNATS Inc
Company Overview
History and Background
Smith & Nephew was founded in 1856 in Hull, England. The company has evolved from a small pharmacy to a global medical technology company focused on advanced wound management, sports medicine, and ENT.
Core Business Areas
- Advanced Wound Management: Develops and markets products for wound care, including chronic wounds, acute wounds, and surgical wounds.
- Sports Medicine: Focuses on arthroscopic repair technologies, including joint repair systems, soft tissue repair products, and regenerative technologies.
- ENT: Provides products and therapies for ear, nose, and throat conditions, including hearing implants and nasal reconstruction.
Leadership and Structure
Smith & Nephew has a board of directors and an executive committee led by the Chief Executive Officer. The organizational structure is divided into business units aligned with the core business areas.
Top Products and Market Share
Key Offerings
- ALLEVYN Wound Dressings: Advanced wound care dressings for a variety of wound types. Competitors: Molnlycke, Convatec. Revenue generated is not directly disclosed per product but estimated to contribute significantaly to the Advanced Wound Management segment, the second largest of the corporation.
- ARTHROCARE Sports Medicine Portfolio: Arthroscopic repair systems for joint and soft tissue repair. Competitors: Stryker, DePuy Synthes.Revenue generated is not directly disclosed per product but estimated to contribute significantaly to the Sports Medicine segment, the largest of the corporation
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulatory scrutiny, and increasing demand due to an aging population and rising healthcare costs.
Positioning
Smith & Nephew is a mid-sized player in the medical technology industry, competing with larger companies in several key segments. Its competitive advantage lies in its specialized expertise and focus on specific therapeutic areas.
Total Addressable Market (TAM)
The global medical device market is estimated to be worth hundreds of billions of USD. Smith & Nephew is positioned to capture a significant portion of this TAM through its focused approach in its core segments.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Focused portfolio
- Established distribution network
- Innovation in key product areas
Weaknesses
- Smaller scale compared to major competitors
- Exposure to reimbursement pressures
- Reliance on specific product lines
- Integration challenges with acquisitions
Opportunities
- Expanding into emerging markets
- Developing new technologies and therapies
- Acquiring complementary businesses
- Partnering with healthcare providers
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Product liability claims
Competitors and Market Share
Key Competitors
- Stryker (SYK)
- Johnson & Johnson (JNJ)
- Medtronic (MDT)
Competitive Landscape
Smith & Nephew competes with larger, more diversified medical technology companies. Its competitive advantage is in specialized areas where it has deep expertise and a strong market presence.
Major Acquisitions
Osiris Therapeutics
- Year: 2019
- Acquisition Price (USD millions): 340
- Strategic Rationale: Expanded regenerative medicine portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth will be analyzed when financials are given
Future Projections: Future Projections will be given when financials are given
Recent Initiatives: Recent strategic initiatives include product launches, acquisitions, and partnerships aimed at expanding market share and driving growth.
Summary
Smith & Nephew is a global medical technology company with a strong presence in wound management, sports medicine, and ENT. While it faces competition from larger players, its focused approach and innovation in specific therapeutic areas give it a competitive edge. Growth opportunities lie in emerging markets and new technologies, but regulatory changes and economic downturns pose potential challenges. Financial data is needed to provide the full picture.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Smith & Nephew Website
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on available estimates and may not be precise. Financial Data will update accordingly if given.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Smith & Nephew SNATS Inc
Exchange NYSE | Headquaters - | ||
IPO Launch date 1999-11-16 | CEO & Director Dr. Deepak S. Nath Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.smith-nephew.com |
Full time employees 17000 | Website https://www.smith-nephew.com | ||
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.